CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF CONDENSED AZACYCLES CANNABINOID RECEPTOR MODULATORS

摘要

The present invention modulates the activity of cannabinoid CB ₂ receptors and, accordingly, CB ₂ receptor-mediated disorders such as osteoarthritis; ache; Hyperalgesia; Allodynia; Inflammatory hyperalgesia; Neuropathic hyperalgesia; Acute pain; osteoporosis; Multiple sclerosis-associated stiffness; Autoimmune disorders; Allergic reactions; For example CNS inflammation; Atherosclerosis; Unwanted immune cell activity and inflammation associated with disorders selected from osteoarthritis, anaphylaxis, Batchet''s disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis and type 1 diabetes ; Age-related macular degeneration; cough; leukemia; Lymphoma; CNS tumors; Prostate cancer; Alzheimer''s disease; Stroke-induced injury; dementia; Amyotrophic lateral sclerosis; And (1aS, 5aS) -2- (4-oxy-pyrazin-2-yl) -1a, 2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa useful for the treatment of Parkinson''s disease It relates to a crystalline form of [a] pentane-4-carboxylic acid ((S) -1-hydroxymethyl-2,2-dimethyl-propyl) -amide (compound 1) and a pharmaceutical composition thereof. Formula I